{"id":19813,"date":"2023-07-06T13:39:16","date_gmt":"2023-07-06T13:39:16","guid":{"rendered":"https:\/\/clinlabint.com\/?p=19813"},"modified":"2023-07-06T13:39:57","modified_gmt":"2023-07-06T13:39:57","slug":"synexa-life-sciences-joins-cepi-cln-to-help-advance-global-epidemic-preparedness-and-response","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/synexa-life-sciences-joins-cepi-cln-to-help-advance-global-epidemic-preparedness-and-response\/","title":{"rendered":"Synexa Life Sciences joins CEPI CLN to help advance global epidemic preparedness and response"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Synexa Life Sciences joins CEPI CLN to help advance global epidemic preparedness and response<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, has joined the Coalition for Epidemic Preparedness Innovations (CEPI) Central Lab Network (CLN). The company says the strategic partnership represents a significant milestone in its commitment to global health security and its dedication to fostering collaboration and innovation in epidemic preparedness and response.<\/h3>\n

<\/p>\n

The CLN is the largest global group using the same methods and materials to standardise and accelerate the evaluation of vaccines against epidemic and pandemic diseases. The CLN is a key enabler of CEPI\u2019s 100 Days Mission, which aims to reduce vaccine development timelines to just 100 days, by helping researchers and regulators evaluate the most promising vaccine candidates quickly and accurately when faced with a future \u2018Disease X\u2019 \u2013 a newly identified pathogen with epidemic or pandemic potential.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Commenting on Synexa\u2019s CEPI membership, Justin Devine, Co-Founder & Chief Innovation Officer at Synexa Life Sciences, said: \u201cSynexa is proud to join the CLN, bolstering CEPI\u2019s network in the Global South and aligning ourselves with the mission of epidemic preparedness and innovation. We are excited to contribute to this global effort to combat emerging infectious diseases and protect lives worldwide. Together, we can accelerate the development and equitable distribution of vaccines, ensuring that vulnerable populations have access to lifesaving interventions. Joining the CLN allows us to harness the power of collaboration, innovation, standardization, and solidarity, as we work towards a healthier, safer future for all.\u201d<\/p>\n

Emile Lens, CEO of Synexa Life Sciences, commented: \u201cJoining CEPI symbolizes the strides Synexa has made over the last decade to become an influential, global player in the biomarker and biopharma industry. We look forward to aligning our resources and leading bioanalytical expertise with the CEPI CLN to leverage collective knowledge and aid the development and deployment of life saving vaccines all over the world\u201d.<\/p>\n

CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched in 2017, to develop vaccines against future epidemics. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need.<\/p>\n<\/div><\/section>
\n